Skip to main content
. 2014 Aug 10;13:309. doi: 10.1186/1475-2875-13-309

Table 2.

Treatment outcomes on day 28, according to study cohort (AL or ASAQ) at various sites in Mozambique

  Study site  
Cohort 1: Artemether-Lumefantrine
 Montepuez
 Dondo
 Chokwe
 Manhiça
 Tete
 TOTAL
Variable
 N = 88
 N = 88
 N = 86
 N = 89
 N = 88
 N = 439
ACPRa (uncorrected) n
 65
 70
 70
 62
 68
 335
ETFb n
 0
 0
 1
 0
 0
 1
LCFc n
 4
 4
 0
 0
 0
 8
LPFd n
 9
 6
 6
 5
 4
 30
New infections (with PCR) n
 9
 7
 4
 3
 2
 25
Recrudescences (with PCR) n
 4
 3
 2
 2
 2
 13
No treatment outcome (loss to follow-up or withdrawn) n
 10
 8
 9
 22
 16
 66
PPe day-28 efficacy (PCR-uncorrected) n/N (95%CI)
 65/78 (83.3) [73.2-90.8]
 70/80 (87.5) [78.2-93.8]
 70/77 (90.9) [82.2-96.3]
 62/67 (92.5) [83.4-97.5]
 68/72 (94.4) [86.4-98.5]
 335/374 (89.6) [86.0-92.5]
PP day-28 efficacy (PCR-corrected) n/N (95%CI)
 65/69 (94.2) [85.8-98.4]
 70/73 (95.9) [88.5-99.1]
 70/73 (95.9) [88.5-99.1]
 62/64 (96.9) [89.2-99.6]
 68/70 (97.) [90.1-99.7]
 335/349 (96.0) [93.4-97.8]
Cohort 2: Artesunate-amodiaquine
 Montepuez
 Dondo
 Chokwe
 Manhiça
 Tete
 TOTAL
Variable
 N = 87
 N = 87
 N = 87
 N = 0
 N = 0
 N = 261
ACPRa (uncorrected) n
 81
 78
 73
 NA
 NA
 232
ETFb n
 0
 0
 0
 NA
 NA
 0
LCFc n
 0
 0
 0
 NA
 NA
 0
LPFd n
 0
 0
 1
 NA
 NA
 1
New infections (with PCR) n
 0
 0
 0
 NA
 NA
 0
Recrudescences (with PCR) n
 0
 0
 1
 NA
 NA
 1
No treatment outcome (loss to follow up or withdrawn) n
 6
 9
 13
 NA
 NA
 28
PP day-28 efficacy (PCR-uncorrected) n/N (95%CI)
 81/81 (100) [NA]
 78/78 (100) [NA]
 73/74 (98.6) [92.7-99.9]
 NA
 NA
 232/233 (99.6) [97.6-99.9]
PP day-28 efficacy (PCR-corrected) n/N (95%CI) 81/81 (100) [NA] 78/78 (100) [NA] 73/74 (98.6) [92.7-99.9] NA NA 232/233 (99.6) [97.6-99.9]

aACPR:adequate clinical and parasitological response; bETF: early treatment failure; cLCF: late clinical failure; dLPF: late parasitological failure; ePP: per protocol; NA: not applicable.